APP13007 Emerging Drug Insight and Market Forecast - 2032

“"APP13007 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about APP13007 for acute ocular pain (AOP) in the eight major markets. A detailed picture of the APP13007 for acute ocular pain in the 8MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada and South Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the APP13007 for acute ocular pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the APP13007 market forecast analysis for acute ocular pain in the 8MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute ocular pain.

Drug Summary:

APP13007 is a nanoparticle formulation of the corticosteroid clobetasol in development for treating postoperative inflammation of the eye. Activus initially developed APP13007 by applying its patented proprietary Activus Pure Nanoparticle Technology (APNT) to the corticosteroid clobetasol propionate to create a novel nanoparticle formulation for treating postoperative inflammation of the eye. Response rate strongly suggests APP13007 outperforms competitors in reducing inflammation and pain for critical Phase III endpoints.

APP13007 completed Phase II studies in 2020 and started Phase III studies in the United States in March 2021.

In Aug 2022, Formosa Pharmaceuticals, Inc. and AimMax Therapeutics, Inc. (United States) reported successful top-line results from CPN-302, the second of the two pivotal Phase III clinical studies of APP13007.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the APP13007 description, mechanism of action, dosage and administration, research and development activities in acute ocular pain.
• Elaborated details on APP13007 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the APP13007 research and development activities in acute ocular pain across the United States, Europe, Canada and South Korea.
• The report also covers the patents information with expiry timeline around APP13007.
• The report contains forecasted sales of APP13007 for acute ocular pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for acute ocular pain.
• The report also features the SWOT analysis with analyst views for APP13007 in acute ocular pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

APP13007 Analytical Perspective by DelveInsight

In-depth APP13007 Market Assessment

This report provides a detailed market assessment of APP13007 for acute ocular pain in the eight major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada and South Korea. This segment of the report provides forecasted sales data from 2023 to 2032.

APP13007 Clinical Assessment

The report provides the clinical trials information of APP13007 for acute ocular pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for acute ocular pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence APP13007 dominance.
• Other emerging products for acute ocular pain are expected to give tough market competition to APP13007 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of APP13007 in acute ocular pain.
• Our in-depth analysis of the forecasted sales data of APP13007 from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the APP13007 in acute ocular pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of APP13007?
• What is the clinical trial status of the study related to APP13007 in acute ocular pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the APP13007 development?
• What are the key designations that have been granted to APP13007 for acute ocular pain?
• What is the forecasted market scenario of APP13007 for acute ocular pain?
• What are the forecasted sales of APP13007 in the eight major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, Canada and South Korea?
• What are the other emerging products available and how are these giving competition to APP13007 for acute ocular pain?
• Which are the late-stage emerging therapies under development for the treatment of acute ocular pain?